HGFR/c-MET Antibody (PSH0-19)

Western Blot: HGFR/c-MET Antibody (PSH0-19) [NBP3-32199] - Western blot analysis of HGFR/c-MET on different lysates with Rabbit anti-HGFR/c-MET antibody (NBP3-32199) at 1/1,000 dilution. Lane 1: A549 cell lysate Lane 2: HepG2 cell lysate Lane 3: HT-29 cell lysate Lane 4: Hela cell lysate Lane 5: LO2 cell lysate Lane 6: SK-Br-3 cell lysate (Negative) Lysates/proteins at 30 ug/Lane. Predicted band size: 156 kDa Observed band size: 145 kDa Exposure time: 1 minute; 6% SDS-PAGE gel. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM/TBST for 1 hour at room temperature. The primary antibody (NBP3-32199) at 1/1,000 dilution was used in 5% NFDM/TBST at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:300,000 dilution was used for 1 hour at room temperature.

Immunohistochemistry: HGFR/c-MET Antibody (PSH0-19) [NBP3-32199] - Immunohistochemical analysis of paraffin-embedded human lung adenocarcinoma tissue with Rabbit anti-HGFR/c-MET antibody (NBP3-32199) at 1/800 dilution. The section was pre-treated using heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) for 20 minutes. The tissues were blocked in 1% BSA for 20 minutes at room temperature, washed with ddH2O and PBS, and then probed with the primary antibody (NBP3-32199) at 1/800 dilution for 1 hour at room temperature. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.

Flow Cytometry: HGFR/c-MET Antibody (PSH0-19) [NBP3-32199] - Flow cytometric analysis of Hela cells labeling HGFR/c-MET. Cells were fixed and permeabilized. Then stained with the primary antibody (NBP3-32199, 1ug/ml) (red) compared with Rabbit IgG Isotype Control (green). After incubation of the primary antibody at +4℃ for an hour, the cells were stained with a iFluor™ 488 conjugate-Goat anti-Rabbit IgG Secondary antibody at 1/1,000 dilution for 30 minutes at +4℃. Unlabelled sample was used as a control (cells without incubation with primary antibody; black).

• Reactivity: Hu
• Applications: WB, Flow, IHC
• Clone: PSH0-19
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 1 mg/ml

HGFR/c-MET Antibody (PSH0-19) Summary

• Additional Information: Recombinant Monoclonal Antibody
• Immunogen: Synthetic peptide within human HGFR/c-MET aa 1,341-1,390 / 1,390. (Uniprot: P08581)
• Localization: Membrane; Secreted.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: MET
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 1:500-1:1000
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 1:800
  • Western Blot 1:1000
• Theoretical MW: 156 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH7.4), 0.1% BSA and 40% Glycerol
• Preservative: 0.05% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for HGFR/c-MET Antibody (PSH0-19)

• AUTS9
• cMET
• c-MET
• EC 2.7.10
• EC 2.7.10.1
• hepatocyte growth factor receptor
• HGF R
• HGF receptor
• HGF/SF receptor
• HGFR
• Met (c-Met)
• met proto-oncogene (hepatocyte growth factor receptor)
• met proto-oncogene tyrosine kinase
• MET
• oncogene MET
• Proto-oncogene c-Met
• RCCP2
• Scatter factor receptor
• SF receptor
• Tyrosine-protein kinase Met

Background

Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: MET